SEMA6B and colorectal carcinoma: Our present study demonstrated that in CRC patients with high SEMA6B expression, the genes involved in the prevention of T-cell priming and the induction of tolerance were increased, and immune checkpoints—such as PD1, PD-L1, CTLA-4, LAG3, TIM-3, and TIGIT—were also upregulated in this group.